Vericel Q2 2025 Earnings Report

Vericel EPS Results

• Actual EPS: N/A
• Consensus EPS: -$0.04
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Vericel Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $64.61 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Vericel Announcement Details

• Quarter: Q2 2025
• Date: 7/31/2025
• Time: Before Market Opens
• Conference Call Date: Thursday, July 31, 2025
• Conference Call Time: 8:30AM ET

Vericel (NASDAQ:VCEL) is a biotechnology company focused on developing and commercializing advanced cell therapies for patients with severe diseases and unmet medical needs. Its core mission is to harness the regenerative potential of autologous cell products to restore tissue function in musculoskeletal and severe burn injuries. The company operates research and manufacturing facilities that support the isolation, expansion and delivery of patient-specific therapeutic cells.

Vericel’s principal commercial products include Epicel®, an autologous cultured epidermal graft approved for the treatment of pediatric and adult patients with deep partial-thickness and full-thickness burns, and MACI® (autologous cultured chondrocytes on porcine collagen membrane), indicated for repairing symptomatic cartilage defects of the knee. These therapies are manufactured from a small biopsy of the patient’s own cells, which are then expanded under controlled conditions and returned for surgical implantation.

Originally formed through a spin-out from Genzyme’s tissue repair business in 2007 under the name Tissue Repair, the company rebranded as Vericel in 2013. It is headquartered in Cambridge, Massachusetts, with a commercial manufacturing site in Hopkinton, Massachusetts. Over the years, Vericel has established quality systems and regulatory expertise to support FDA-approved cell therapy manufacturing and distribution.

Vericel markets its products primarily in the United States, selling directly to hospitals and surgical centers that treat severe burn and cartilage injury patients. Under the leadership of President and Chief Executive Officer Jonathan G. Beck, the company is also advancing its pipeline of next-generation cell therapies and exploring strategic collaborations to broaden its geographic footprint and address new indications. Vericel’s ongoing clinical and manufacturing investments aim to enhance patient access to regenerative treatments in orthopedics and reconstructive medicine.